Loading...
Docoh

Adicet Bio (ACET)

News

From Benzinga Pro
12 Health Care Stocks Moving In Monday's After-Market Session
6 Jun 22
Movers
Gainers Vaxxinity (NASDAQ:VAXX) stock moved upwards by 10.2% to $3.56 during Monday's after-market session. The company's market cap stands at $448.5 million.
Adicet Bio Reports Emerging Data From ADI-001 Phase 1 Trial At The American Society Of Clinical Oncology Annual Meeting
6 Jun 22
Biotech, News, Events, General
ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin’s Lymphoma (NHL), as of May 31,
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
5 Jun 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.
70 Biggest Movers From Friday
31 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
41 Stocks Moving In Friday's Mid-Day Session
27 May 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
20 Stocks Moving in Friday's Pre-Market Session
27 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma.
12 Health Care Stocks Moving In Thursday's After-Market Session
26 May 22
Movers
Gainers
Adicet Bio Q1 EPS $0.10 Up From $(0.82) YoY
12 May 22
Earnings, News
Adicet Bio (NASDAQ:ACET) reported quarterly earnings of $0.10 per share. This is a 112.2 percent increase over losses of $(0.82) per share from the same period last year.

Press releases

From Benzinga Pro
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1 Jul 22
Press Releases
Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on June 30, 2022
Adicet Bio to Present at Upcoming Investor Conferences
21 Jun 22
Press Releases
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
6 Jun 22
Press Releases
ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin's Lymphoma (NHL), as of May 31, 2022
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3 Jun 22
Press Releases
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on May 31, 2022 (the
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
26 May 22
Press Releases
As of the February 14, 2022 ASCO abstract data-cut date, ADI-001 demonstrated a 67% complete response rate with positive preliminary durability data and a favorable safety and tolerability profile Updated data from a
Adicet Bio to Present at Upcoming Investor Conferences
18 May 22
Press Releases
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
12 May 22
Press Releases
Interim data from ADI-001 Phase 1 trial accepted for oral presentation at 2022 ASCO Annual Meeting Strong balance sheet with $277.9 million in cash and cash equivalents as of March 31, 2022 Adicet Bio, Inc.
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
5 May 22
Press Releases
ADI-001 exhibited robust in vitro and in vivo tumor growth inhibition in multiple human lymphoma cell lines, with adaptive and innate mechanisms contributing to its anti-tumor activity Non-gene-edited ADI-001 gamma
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4 May 22
Press Releases
Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on April 29, 2022
Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
27 Apr 22
Press Releases
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that
Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
19 Apr 22
Press Releases
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced the
Adicet Bio to Participate in Upcoming Investor Conferences
7 Apr 22
Press Releases
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that